Coagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19

Skrócona strona pozycji
dc.contributor.authorCzarnecka-Czapczyńska, Magdalena
dc.contributor.authorBartusik-Aebisher, Dorota
dc.contributor.authorKrupka-Olek, Magdalena
dc.contributor.authorAebisher, David
dc.contributor.authorCieślar, Grzegorz
dc.contributor.authorLatos, Wojciech
dc.contributor.authorKawczyk-Krupka, Aleksandra
dc.date.accessioned2021-11-02T08:25:16Z
dc.date.available2021-11-02T08:25:16Z
dc.date.issued2021
dc.description.abstractIntroduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2). Aim. The aim of this article is to discuss epidemiology of thromboembolic complication in COVID-19. Material and methods. This article is a review done in regards to discuss clinical features of the anticoagulation treatment in COVID-19. Analysis of the literature. A review is discussed an anticoagulation treatment in 41 manuscripts. Conclusion. Most commonly coagulation abnormalities in patient with COVID-19 is mild thrombocytopenia. Apart from their typical role in thrombosis and hemostasis, platelets mediate key aspects of immune and inflammatory.pl_PL.UTF-8
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 19, z. 3 (2021), s. 241–245pl_PL.UTF-8
dc.identifier.doi10.15584/ejcem.2021.3.5
dc.identifier.eissn2544-1361
dc.identifier.issn2544-2406
dc.identifier.urihttp://repozytorium.ur.edu.pl/handle/item/6852
dc.language.isoengpl_PL.UTF-8
dc.publisherWydawnictwo Uniwersytetu Rzeszowskiegopl_PL.UTF-8
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectanticoagulationpl_PL.UTF-8
dc.subjectcoagulation abnormalitiespl_PL.UTF-8
dc.subjectCOVID-19pl_PL.UTF-8
dc.titleCoagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19pl_PL.UTF-8
dc.typereviewpl_PL.UTF-8
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
5 czarnecka-czapczyńska-coagulation.pdf
Rozmiar:
158.59 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.22 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.19, z. 3 (2021)